Sirolimus pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "sirolimus pharmacology"
Sirolimus Mechanism of Action and Immunosuppressive Properties
Sirolimus, also known as rapamycin, is a macrocyclic antibiotic with a unique immunosuppressive mechanism. It forms a complex with the intracellular protein FKBP12, which then inhibits the mammalian target of rapamycin (mTOR). This inhibition blocks cell-cycle progression at the G1 to S phase transition, suppressing the proliferation of T cells and B cells, and reducing antibody production. This mechanism is distinct from other immunosuppressants like cyclosporine and tacrolimus, making sirolimus valuable in organ transplantation and other immune-related conditions 126.
Pharmacokinetics of Sirolimus: Absorption, Distribution, Metabolism, and Elimination
Sirolimus is characterized by rapid absorption (peak concentration in 1–2 hours), but it has low oral bioavailability (about 14–15%) due to extensive first-pass metabolism in the liver and intestinal wall, primarily by CYP3A4 and P-glycoprotein. The drug exhibits a large volume of distribution (1.7 L/kg), indicating extensive tissue partitioning, especially into adipose tissue. Sirolimus has a prolonged terminal half-life (57–63 hours), and both inter- and intra-patient variability in clearance are high 1234.
Factors Influencing Sirolimus Pharmacokinetics and Variability
The pharmacokinetics of sirolimus are highly variable between individuals. Factors contributing to this variability include age, weight, liver function, genetic polymorphisms (especially in CYP3A5), cyclosporine exposure, sirolimus dose, serum creatinine, and concurrent medications that affect CYP3A or P-glycoprotein activity. In children, especially neonates and infants, sirolimus clearance can change rapidly as metabolic pathways mature, necessitating frequent dose adjustments and close monitoring 1347+1 MORE.
Therapeutic Drug Monitoring and Dosing Strategies
Due to its narrow therapeutic window and high variability, therapeutic drug monitoring (TDM) is recommended for sirolimus, especially in patients with hepatic impairment, children, those on interacting drugs, or at high risk of rejection. The target whole-blood concentration is typically 5–15 ng/mL. Dose adjustments should be based on trough levels measured at least 5–7 days after a change, as steady state is reached slowly. Model-informed precision dosing and pharmacokinetic models can help optimize therapy, particularly in pediatric populations 1478.
Clinical Efficacy and Adverse Effects
Sirolimus is effective in reducing acute rejection rates in renal transplant recipients when used with cyclosporine and corticosteroids. It also allows for potential reduction in the use of other immunosuppressants. Common adverse effects include hypercholesterolemia, hypertriglyceridemia, hypertension, diarrhea, increased creatinine, hypokalemia, leukopenia, and thrombocytopenia. Monitoring and individualized dosing are important to minimize toxicity 12.
Sirolimus in Immune Regulation and Tolerance
Sirolimus not only suppresses immune responses but also promotes immune tolerance by amplifying regulatory B cells (Bregs) and regulatory T cells (Tregs). This effect may help reduce the risk of rejection and certain complications, such as biliary stenosis, in transplant patients. The cytokines IL-10 and TGF-β1 play key roles in this regulatory process .
Comparison with Other mTOR Inhibitors
Compared to everolimus, another mTOR inhibitor, sirolimus has lower bioavailability, a longer half-life, and different tissue distribution and metabolic profiles. These differences can influence their clinical use, side effect profiles, and interactions with other drugs .
Conclusion
Sirolimus is a potent immunosuppressant with a unique mechanism of action and complex pharmacokinetics. Its use requires careful consideration of individual patient factors, therapeutic drug monitoring, and sometimes model-informed dosing to achieve optimal efficacy and safety. Sirolimus also has beneficial effects on immune regulation, making it a valuable agent in transplantation and other immune-mediated conditions 1234+5 MORE.
Sources and full results
Most relevant research papers on this topic
Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.
Sirolimus effectively prevents acute renal allograft rejection when used in an immunosuppressive regimen with a understanding of its clinical pharmacokinetics, concentration-effect relationship, and therapeutic drug monitoring.
Sirolimus: a new agent for prevention of renal allograft rejection.
Sirolimus effectively prevents acute renal allograft rejection after transplantation, potentially reducing the need for cyclosporine and corticosteroids.
DOI